2008
DOI: 10.1007/s12070-008-0087-9
|View full text |Cite
|
Sign up to set email alerts
|

Primary B cell lymphoma of paranasal sinuses: a diagnostic surprise

Abstract: Primary lymphomas of paranasal cavities are rather uncommon entities. They have a variable presentation from fulminant destructive manifestations to chronic indolent type of disease. Chronic indolent form may mimic invasive fungal sinusitis in its presentation. Unless high index of suspicion is held and appropriate histopathology sections are taken from specimen, its diagnosis can be deceitful. We here by report a case of primary lymphoma of the paranasal sinuses which was radiologically and clinically suspect… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 7 publications
0
3
0
Order By: Relevance
“…In a review of 852 cases, the one-year survival rate of sinonasal tract DLBCL was 84.7% and the 5-years urvival rate was 68.0%. 9 Chemotherapy is recommended for the treatment for DLBCL and it is the same as for both nodal and extranodal diseases. The principle is based on that DLBCL of the head and neck is a localized manifestation of systemic disease.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In a review of 852 cases, the one-year survival rate of sinonasal tract DLBCL was 84.7% and the 5-years urvival rate was 68.0%. 9 Chemotherapy is recommended for the treatment for DLBCL and it is the same as for both nodal and extranodal diseases. The principle is based on that DLBCL of the head and neck is a localized manifestation of systemic disease.…”
Section: Discussionmentioning
confidence: 99%
“…It had been noted that cases with more than one sinus involvement had lower survival rates. 9 DLBCL was very aggressive and the treatment was inefficient to prevent CNS metastasis depending only on the rituximab, which is not effectively cross blood brain barrier. 10 CNS involvement upstaged the Ann Arbor staging to IV with in less than four months despite the chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…Further, nodules were leached with dilute HCl using pyrite, sodium sulfite, and carbon as reductant , or using alcohol modified hydrochloric acid leaching (Jana et al, 1995). Diluted H 2 SO 4 has generally been used as a leachant along with activated carbon (Saito, 1988), charcoal (Anand 1987), patent, Indian IN 1987, Cl C 22 B 3/00) and acetylene black (Myazaki and Kitamura, 1985) as the reducing agents. The other reducing agents tried in sulfuric acid media and patented are syrup, saccharose, glucose, H 2 O 2 and oxalic acid.…”
Section: Methods Used For Dissolution or Leaching Of The Nodulementioning
confidence: 99%